The suppression of IDO1 induction by carfilzomib could enhance its therapeutic activity in myeloma, a problem potentially exacerbated by the apparent ability of carfilzomib alone to induce some IL1B and IL6 expression (Figures 3B, C). This evidence concerns the gene IL6 and plasma cell myeloma.